Tempus AI, Inc. (Nasdaq: TEM), a healthcare technology company specializing in AI-enabled precision medicine solutions, experienced a sharp decline in its stock price following the release of a short report by Spruce Point Capital Management. The report criticized Tempus AI's leadership for a questionable track record, aggressive accounting practices, and reliance on AI hype despite AI representing only 2% of its revenue. Spruce Point projected a potential 50-60% downside for the stock. Following the report's publication, TEM shares fell as much as 18%, marking one of the worst trading days in the company's history. The report also highlighted concerns about the management team's past involvement with controversial companies and alleged financial irregularities. Despite the negative market reaction, some investors viewed the dip as a buying opportunity, referencing a similar short report on TMDX that preceded a strong recovery. Concurrently, multiple securities fraud investigations have been announced involving Tempus AI, with law firms encouraging investors who suffered losses to contact them. Prior to the report, Tempus AI shares had risen on news of a new study demonstrating the impact of Ambry Genetics’ Patient for Life™ Program on rare disease diagnosis. The stock had traded above $66 before the decline and was seen trading near the $60 level after the selloff.